Page 43 - Read Online

Gasparello et al. J Cancer Metastasis Treat 2019;5:52 I http://dx.doi.org/10.20517/2394-4722.2019.17 Page 11 of
11
69. Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, et al. Circulating and disseminated tumor cells from breast cancer patient-
derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res 2015;17:3.
70. Waters PS, McDermott AM, Wall D, Heneghan HM, Miller N, et al. Relationship between circulating and tissue microRNAs in a
murine model of breast cancer. PLoS One 2012;7:e50459.
71. Zhang G, Zhang W, Li B, Stringer-Reasor E, Chu C, et al. MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis
and associated with tumor metastasis in breast cancer. Breast Cancer Res 2017;19:73.
72. Zhou ZP, Wang LP, Hong ZS, Qiu CZ, Wang MZ, et al. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29
colon cancer cells via multiple signaling pathways. Int J Oncol 2018;53:1183-92.
73. Bai B, Chen X, Zhang R, Wang X, Jiang Y, et al. Dual-agonist occupancy of orexin receptor 1 and cholecystokinin A receptor
heterodimers decreases G-protein-dependent signaling and migration in the human colon cancer cell line HT-29. Biochim Biophys Acta
Mol Cell Res 2017;1864:1153-64.
74. Maeda K, Maeda T, Qi Y. In vitro and in vivo induction of human LoVo cells into apoptotic process by non-invasive microwave
treatment: a potentially novel approach for physical therapy of human colorectal cancer. Oncol Rep 2004;11:771-5.
75. Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett 2014;588:99-104.
76. Xu K, Liang X, Shen K, Sun L, Cui D, et al. MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-
regulating ADAM-17. Exp Cell Res 2012;318:2168-77.
77. Dou H, Wang Y, Su G, Zhao S. Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer. Int J Clin
Exp Med 2015;8:9291-8.
78. Yu H, Jiang L, Sun C, Li Guo L, Lin M, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung
cancer. Gene 2014;534:60-5.
79. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, et al. Circulating microRNAs as novel minimally invasive biomarkers for
breast cancer. Ann Surg 2010;251:499-505.
80. Pérez-Ramírez C, Cañadas-Garre M, Robles AI, Molina MÁ, Faus-Dáder MJ, et al. Liquid biopsy in early stage lung cancer. Transl
Lung Cancer Res 2016;5:517-24.
81. Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, et al. Implementing liquid biopsies into clinical decision
making for cancer immunotherapy. Oncotarget 2018;8:48507-20.
82. Nikolaev S, Lemmens L, Koessler T, Blouin JL, Nouspikel T. Circulating tumoral DNA: Preanalytical validation and quality control in
a diagnostic laboratory. Anal Biochem 2018;542:34-9.
83. Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, et al. Obesity- dependent metabolic signatures associated with
nonalcoholic fatty liver disease progression. J Proteome Res 2012;11:2521-32.
84. Kim J, Easley CJ. Isothermal DNA amplification in bioanalysis: strategies and applications. Bioanalysis 2011;3:227-39.
85. D'Agata R, Spoto G. Surface plasmon resonance imaging for nucleic acid detection. Anal Bioanal Chem 2013;405:573-84.
86. Das J, Ivanov I, Montermini L, Rak J, Sargent EH, et al. An electrochemical clamp assay for direct, rapid analysis of circulating nucleic
acids in serum. Nat Chem 2015;7:569-75.